오로라 키나아제 C : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

오로라 키나아제 C(Aurora Kinase C)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관에서 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

1. 서론

• 조사 범위

2. 오로라 키나아제 C 개요

3. 치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

4. 파이프라인 제품 상황 개요

• 후기 단계 제품
• 초기 단계 제품

5. 기업에서 개발중인 제품

6. 치료제 평가

• 단일요법/병용 치료제별
• 작용기전별
• 투여 경로별
• 분자 종류별

7. 치료제 개발에 참여하고 있는 기업

• AbbVie Inc.
• Amgen Inc.
• Nemucore Medical Innovations, Inc.
• Sanofi
• Vertex Pharmaceuticals Incorporated

8. 약제 개요

9. 휴지 상태인 프로젝트

10. 개발이 중지된 제품

11. 부록

12. 도표

List of Tables

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Therapy Areas, H2 2019
• Number of Products under Development by Indication, H2 2019
• Number of Products under Development by Companies, H2 2019
• Products under Development by Companies, H2 2019
• Number of Products under Investigation by Universities/Institutes, H2 2019
• Products under Investigation by Universities/Institutes, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Stage and Route of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019
• Pipeline by AbbVie Inc, H2 2019
• Pipeline by Amgen Inc, H2 2019
• Pipeline by Cielo Therapeutics Inc, H2 2019
• Pipeline by Nemucore Medical Innovations Inc, H2 2019
• Dormant Products, H2 2019
• Dormant Products, H2 2019 (Contd..1), H2 2019
• Dormant Products, H2 2019 (Contd..2), H2 2019
• Discontinued Products, H2 2019

List of Figures

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Top 10 Indications, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Routes of Administration, H2 2019
• Number of Products by Stage and Routes of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019

Summary

According to the recently published report 'Aurora Kinase C - Pipeline Review, H2 2019'; Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Aurora Kinase C is a member of the Aurora subfamily of serine/threonine protein kinases. Aurora Kinase C is a chromosomal passenger protein that forms complexes with Aurora-B and inner centromere proteins and plays an important role in organizing microtubules in relation to centrosome function during mitosis. It is over expressed in several cancer cell lines and involved in oncogenic signal transduction.

The report 'Aurora Kinase C - Pipeline Review, H2 2019' outlays comprehensive information on the Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ovarian Cancer, Solid Tumor, Breast Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer and Triple-Negative Breast Cancer (TNBC).

Scope

• The report provides a snapshot of the global therapeutic landscape for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)
• The report reviews Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Overview
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Companies Involved in Therapeutics Development
• AbbVie Inc
• Amgen Inc
• Cielo Therapeutics Inc
• Nemucore Medical Innovations Inc
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Drug Profiles
• AMG-900 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• CCT-137690 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• danusertib - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• ilorasertib - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• NMI-900 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Dormant Products
• Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Discontinued Products
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer